The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Apr 12

PMID 35409316

Authors

Eitan Giat

Ilan Ben-Zvi

Merav Lidar

Avi Livneh

Affiliations

Soon will be listed here.

Abstract

Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness to colchicine, the cornerstone of FMF treatment, is nowadays addressed by IL-1- blockers. Each of the two IL-1 blockers currently used in FMF, anakinra and canakinumab, has its own merits for FMF care. Here we focus on anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, and explore the literature by using PubMed regarding the utility of anakinra in certain conditions of FMF. Occasionally we enrich published data with our own experience. To facilitate insights to anakinra role, the paper briefs some clinical, genetic, pathogenetic, and management aspects of FMF. The clinical settings of FMF covered in this review include colchicine resistance, AA amyloidosis, renal transplantation, protracted febrile myalgia, on- demand use, leg pain, arthritis, temporary suspension of colchicine, pediatric patients, and pregnancy and lactation. In many of these instances, either because of safety concerns or a necessity for only transient and short-term use, anakinra, due to its short half-life, is the preferred IL-1 blocker.

Citing Articles

Protracted febrile myalgia syndrome in children with familial Mediterranean fever - systematic review and a case report.

Hospach T, Blankenburg F, Heinkele A, von Kalle T, Uziel Y, Kallinich T Pediatr Rheumatol Online J. 2024; 22(1):85.

PMID: 39256780 PMC: 11389256. DOI: 10.1186/s12969-024-01019-6.

IL-1R Mediated Activation of Renal Sensory Nerves in DOCA-Salt Hypertension.

Baumann D, Van Helden D, Evans L, Vulchanova L, Dayton A, Osborn J Hypertension. 2024; 81(8):1811-1821.

PMID: 38841853 PMC: 11254549. DOI: 10.1161/HYPERTENSIONAHA.123.22620.

Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?.

Oner N, Celikel E, Ekici Tekin Z, Gungorer V, Kurt T, Sezer M Croat Med J. 2023; 64(5):354-361.

PMID: 37927190 PMC: 10668039.

The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever.

Cebeci S, Yildiz M, Gunalp A, Cebi M, Kilinc B, Pinar E Rheumatol Int. 2023; 44(11):2569-2575.

PMID: 37277620 DOI: 10.1007/s00296-023-05351-0.

References

Haj-Yahia S, Ben-Zvi I, Lidar M, Livneh A . Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases. Joint Bone Spine. 2021; 88(5):105201. DOI: 10.1016/j.jbspin.2021.105201. View

Sarkisian T, Ajrapetian H, Beglarian A, Shahsuvarian G, Egiazarian A . Familial Mediterranean Fever in Armenian population. Georgian Med News. 2008; (156):105-11. View

Padeh S, Livneh A, Pras E, Shinar Y, Lidar M, Feld O . Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol. 2010; 37(4):865-9. DOI: 10.3899/jrheum.090687. View

Kisacik B, Yildirim B, Tasliyurt T, Ozyurt H, Ozyurt B, Yuce S . Increased frequency of familial Mediterranean fever in northern Turkey: a population-based study. Rheumatol Int. 2009; 29(11):1307-9. DOI: 10.1007/s00296-009-0849-z. View

GOLDFINGER S . Colchicine for familial Mediterranean fever. N Engl J Med. 1972; 287(25):1302. DOI: 10.1056/NEJM197212212872514. View

Giaglis S, Papadopoulos V, Kambas K, Doumas M, Tsironidou V, Rafail S . MEFV alterations and population genetics analysis in a large cohort of Greek patients with familial Mediterranean fever. Clin Genet. 2007; 71(5):458-67. DOI: 10.1111/j.1399-0004.2007.00789.x. View

Kishida D, Nakamura A, Yazaki M, Oka K, Tsuchiya-Suzuki A, Ichikawa T . Triggering factors for febrile attacks in Japanese patients with familial Mediterranean fever. Clin Exp Rheumatol. 2020; 38 Suppl 127(5):76-79. View

Kuemmerle-Deschner J, Gautam R, George A, Raza S, Lomax K, Hur P . A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. Rheumatology (Oxford). 2020; 59(10):2711-2724. DOI: 10.1093/rheumatology/keaa205. View

Fidder H, Chowers Y, Lidar M, Sternberg M, Langevitz P, Livneh A . Crohn disease in patients with familial Mediterranean fever. Medicine (Baltimore). 2002; 81(6):411-6. DOI: 10.1097/00005792-200211000-00001. View

10.

Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N . Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010; 157(2):310-315.e1. DOI: 10.1016/j.jpeds.2010.02.040. View

11.

Yeter H, Yetkin N, Akcay O, Derici U, Arinsoy T . Late Acute Cellular Rejection After Anakinra Treatment in a Kidney Transplant Patient, Is It a Coincidence?. Iran J Kidney Dis. 2020; 14(4):318-320. View

12.

Ben-Zvi I, Brandt B, Berkun Y, Lidar M, Livneh A . The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). Gene. 2011; 491(2):260-3. DOI: 10.1016/j.gene.2011.10.005. View

13.

Simon A, Bodar E, van der Hilst J, van der Meer J, Fiselier T, Cuppen M . Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004; 117(3):208-10. DOI: 10.1016/j.amjmed.2004.02.039. View

14.

Cakan M, Karadag S, Aktay Ayaz N . Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever. North Clin Istanb. 2020; 7(1):78-80. PMC: 7103750. DOI: 10.14744/nci.2019.38243. View

15.

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

16.

Ugurlu S, Ergezen B, Egeli B, Selvi O, Ozdogan H . Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2020; 59(12):3892-3899. DOI: 10.1093/rheumatology/keaa211. View

17.

Shohat M, Shohat T, Rotter J, Schlesinger M, Petersen G, Pribyl T . Serum amyloid A and P protein genes in familial Mediterranean fever. Genomics. 1990; 8(1):83-9. DOI: 10.1016/0888-7543(90)90228-m. View

18.

Kara Eroglu F, Besbas N, Topaloglu R, Ozen S . Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015; 35(10):1733-7. DOI: 10.1007/s00296-015-3293-2. View

19.

. Familial Mediterranean fever. Recent advances in pathogenesis and management. West J Med. 1977; 127(1):15-23. PMC: 1237671. View

20.

Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, SOHAR E . The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996; 26(3):612-27. DOI: 10.1016/s0049-0172(96)80012-6. View